

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tadamitsu KISHIMOTO, et al.


Title: CHRONIC RHEUMATOID ARTHRITIS THERAPY CONTAINING  
IL-6 ANTAGONIST AS EFFECTIVE COMPONENT

Appl. No.: 09/756,125

Filing Date: 01/09/2001

Examiner: F. Pierre VanderVegt, Ph.D.

Art Unit: 2 1644



Commissioner for Patents  
Washington, D.C. 20231

TERMINAL DISCLAIMER

Sir:

The undersigned authorized agent of the assignee certifies that, to the best of his/her knowledge and belief, the assignee is the holder of the entire right, title and interest of the above-captioned application by virtue of an Assignment (copy attached), which he/she has duly reviewed, recorded on or about April 7, 1997, (Reel 8525, Frame 0517, in Serial No. 08/817,084), which documents have been reviewed, and, through the undersigned officer who is authorized to sign this document on behalf of said assignee, hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of U.S. Patent No. 5,888,510, and hereby agrees that any patent so granted on the above-identified application Ser. No. 09/756,125 shall be enforceable only for and during such period that the legal title to United States Patent No. 5,888,510 shall be the same as for said patent, this agreement to run with any patent granted on the above-identified application Ser. No. 09/756,125 and to be binding upon the grantee, its successor, or assigns.

The undersigned authorized representative of the assignee does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of U.S. Patent

09/25/2001 BNGUYEN1 00000003 09756125

02 FC:148

002.639819.1

110.00 OP

TECH CENTER 1600/2900

SEP 25 2001

RECEIVED

No. 5,888,510 in the event that either of said patents later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The undersigned authorized representative of the assignee hereby declares that all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

9/20/2001  
Date

Signature: Masao Haruna  
Name: Masao Haruna  
Title: Head, Patent Section  
Intellectual Property Department  
Chugai Pharmaceutical Co., Ltd.